2025年9月16日，山东步长制药股份有限公司第五届董事会第三十二次会议通过议案，其控股子公司上 海合璞医疗科技有限公司拟共投资490万元，分别与济南恒德科技、上海裹鼎科技设立山东合璞锐诚医 疗科技有限公司、湖北合璞医疗科技有限公司，上海合璞均持股70%。近日，两家新公司完成工商登记 注册手续。山东合璞锐诚医疗科技注册资本400万元，9月24日成立；湖北合璞医疗科技注册资本300万 元，9月26日成立。相关信息已在上海证券交易所网站披露。 ...

Core Insights - The 6th China Liaoning International Investment and Trade Fair (Liaoning Fair) was held from September 25 to 28, 2023, in Shenyang, serving as a significant platform for expanding Liaoning's international cooperation and trade [3][4] - The fair attracted over 60 countries' officials, business leaders, and representatives from Fortune 500 companies, highlighting its importance in fostering global economic ties [4] Group 1: Investment and Trade Opportunities - The fair showcased various products, including an AI-assisted pathology image analysis system, indicating a focus on technological advancements in healthcare [3] - Japanese enterprises have consistently participated in the fair, signing cooperation agreements with Chinese food companies, demonstrating effective international collaboration [3] - The presence of South Korean companies, such as the automotive filter manufacturer, reflects the fair's role in facilitating business expansion and partnerships in the region [3] Group 2: Economic Growth and Foreign Investment - Liaoning's geographical advantages, including its location in the Northeast Asia economic circle and its role in the Belt and Road Initiative, enhance its appeal for foreign investment [3] - In the first half of the year, Liaoning attracted $2.87 billion in foreign direct investment, marking a 126.3% year-on-year increase [5] - The province's total import and export value reached 501.94 billion yuan in the first eight months, with exports hitting a record high of 267.67 billion yuan, reflecting robust economic performance [5]

Core Insights - The MedBench platform has released its latest evaluation results for 2025, highlighting the "Zhuomuniao Medical Model" from Zhongkang Technology, which ranked 2nd overall and 1st in medical language understanding, showcasing its significant advantages in integrating natural language processing with medical expertise [1] Group 1: Model Performance - The "Zhuomuniao Medical Model" is built on nearly two decades of data accumulation and industry insights from Zhongkang Technology, utilizing a high-quality training resource that includes over one million medical documents, guidelines, textbooks, and drug instructions, as well as tens of millions of de-identified clinical data, disease records, and unstructured medical records [1] - The model has a parameter count of 70 billion, and its performance is enhanced through large-scale pre-training and multi-stage instruction fine-tuning, along with advanced techniques such as data cleaning, deduplication, and augmentation [1] Group 2: Application and Impact - The "Zhuomuniao Medical Model" serves as an intelligent engine that spans the entire health service chain, supporting the "Healthcare Full-Scenario Intelligent Body" launched by Zhongkang Technology in March 2025 [1] - This intelligent body is developed using the Tiangong No. 1 and Zhuomuniao medical platforms, integrating high-quality industry data, professional knowledge, and leading model distillation technology to create intelligent solutions for various scenarios including commercial, medical, pharmacy, health management, and research [1] - These intelligent bodies are designed to achieve a business closed-loop characterized by "intelligent decision-making, agile action, and controllable results," thereby enhancing efficiency and service quality in the healthcare industry [1]

想象一下去医院看病，人工智能（AI）系统根据患者的检查数据实时自动生成治疗方案，经医生审查后，如果患者和医生皆不反对就直接执行该方案—— 这不是科幻，而是中国医学科学院血液病医院（中国医学科学院血液学研究所）信息与资源中心首席技术专家陈俊仁和姜尔烈团队的最新技术突破。近日， 上述团队在《自然·通讯》杂志发表文章，首次报道条件式自主AI开立药物处方的临床实践。 陈俊仁表示，当前AI的临床医学应用多是"辅助型AI"。好比社交平台的智能引擎推送个性化的新闻信息，辅助型的医疗AI基于患者情况生成个性化的医学 专业信息，接着医生和患者决定是否采纳该信息并共同决定如何根据AI所提供的信息制定诊治方案。 然而，随着AI迅速深入到人类日常生活的多个方面，条件式自主AI模式也越来越普遍。例如汽车驾驶导航软件不仅提供空间地图信息和实时路况，而且可 直接计算出最优驾驶路线。 研究团队认为，未来AI临床应用也可能采取条件式自主模式，即AI制定医疗方案作为默认选项，若医生和患者不否决就执行该默认方案。研究团队假设， 在满足三个条件的情况下，医生和患者更可能愿意接受使用条件式自主AI生成医疗方案：一、除了AI手段之外没有其他方法能精准判 ...

Core Viewpoint - The article discusses the recent investment by ASML in the AI unicorn Mistral AI, highlighting the significance of this deal in the context of Europe's venture capital landscape and its struggle to compete with the US and China in the AI sector [4][5][16]. Investment Landscape - In 2023, Europe saw a total of $8 billion in AI venture capital investments, significantly lagging behind the US at $68 billion and China at $15 billion [4]. - By 2024, the situation improved slightly with Europe reaching $11 billion, while the US secured $47 billion, indicating a persistent gap [5]. Mistral AI's Financing - Mistral AI recently completed a Series C funding round, raising €1.7 billion (approximately ¥14.2 billion) with a post-money valuation of €11.7 billion (approximately ¥97.8 billion) [5][7]. - ASML led this funding round, contributing €1.3 billion (approximately ¥10.9 billion) for an 11% equity stake [7]. Strategic Implications - The partnership between ASML and Mistral AI is seen as a significant move for Europe, aiming to enhance technological sovereignty and reduce reliance on US tech companies [8][9]. - Mistral AI plans to use the funds to develop customized decentralized AI solutions for industrial applications, aligning with ASML's goals to improve its product offerings [9][10]. Market Position and Challenges - Despite its high valuation, Mistral AI holds only a 2% market share in the large model AI sector, facing stiff competition from established players like Deepseek and OpenAI [10][11]. - The company’s revenue model is heavily reliant on a few large contracts, raising concerns about its sustainability and ability to compete in the rapidly evolving AI landscape [11][12]. Political and Economic Context - The investment is viewed by some as politically motivated, given the background of Mistral AI's co-founder, who previously served in the French government [12][14]. - The article suggests that ASML's investment could be a strategic move to bolster Europe's industrial capabilities in AI, reflecting a shift in focus towards vertical applications rather than consumer-facing products [16][17]. Future Outlook - The article concludes that while the investment provides Mistral AI with necessary resources, the broader European venture capital ecosystem must adapt to compete effectively in AI, particularly in specialized applications like healthcare [16][18].

编译丨王聪 编辑丨王多鱼 排版丨水成文 医疗 AI 智能体 （ medical AI agent ）代表了医疗保健领域的变革性范式，其 自主性 、 适应性 和对复杂任务的 决策能力 使其区别于传统的人工智能。 2025 年 9 月 26 日，澳门科技大学 张康 、 霍文逊 、澳门城市大学 印赟 、解放军总医院第一医学中心 陈香美 院士、中山大学肿瘤防治中心 骆卉妍 等在 Cell 子刊 Cell Reports Medicine 上发表了题为： A foundational architecture for AI agents in healthcare 的综述论文。 该综述提出了一个基于四大核心组件—— 规划 、 行动 、 反思 与 记忆 的 医疗 AI 智能体 概念框架，重点考察该框架在关键临床领域的应用——从提升诊断准确 率、个性化治疗方案，到指导机器人手术和实现实时患者监测。研究深入分析了实施过程中面临的多重挑战，包括技术集成、临床医生接受度、法规适应性，以 及数据隐私和算法偏见等伦理问题。未来发展方向包括向主动式多智能体协作系统的转型，以及具有前瞻性的" AI 智能体医院 "概念。尽管这些智能体系统 ...

Core Insights - Ark Health (06086) saw a significant increase of over 8%, reaching HKD 4.34 with a trading volume of HKD 40.77 million, following a report in Nature highlighting China's innovative chronic disease management model that integrates AI [1] Group 1: Industry Overview - The report in Nature emphasizes China's unique approach to chronic disease management, which effectively combines AI with various chronic disease management strategies, making it a rare example globally [1] - The emergence of new AI technologies, particularly large models, has created a new wave of innovation in the healthcare sector, with Ark Health positioned to capitalize on these trends [1] Group 2: Company Developments - Ark Health's "super digital brain," the Xing Shi large model, powers five major applications: AI medication assistant, AI health steward, AI doctor assistant, AI academic assistant, and AI search, each tailored for specific clinical and patient scenarios [2] - The AI academic assistant product enhances efficiency by providing expert-level answers with voice interaction capabilities, catering to the busy schedules of clinical doctors [2]

Group 1 - The core viewpoint of the articles highlights the significant rise of Ark Health (方舟健客) stock, which increased by 8.23% to HKD 4.34, with a trading volume of HKD 40.77 million, following a report in Nature about China's medical AI models [1] - The Nature report emphasizes China's chronic disease management model, which integrates AI with various chronic disease management practices, showcasing a successful case that is rare globally [1] - The report indicates that while there are few large-scale companies in the overseas market that deeply integrate AI with chronic disease management, China's innovative forces are emerging in this field, potentially allowing for a leapfrog development [1] Group 2 - Ark Health's "super digital brain," the Xing Shi model, drives five major applications: AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, each tailored for specific clinical and patient scenarios [2] - Each application provides real-time and precise assistance in areas such as medication guidance, patient education, diagnostic support, and medical literature queries [2] - The AI academic assistant product enhances efficiency and user engagement by offering expert-level answers with voice interaction capabilities, catering to the busy clinical environment of doctors [2]

Core Insights - The State Council has issued the "Opinions on Deepening the Implementation of 'Artificial Intelligence+' Actions," indicating that AI will be a key digital technology for various industries moving forward [1] - The launch of the "Medical Imaging Large Model Intelligent Computing Integrated Machine MIIA-X1" by Yipai Sunshine and Yinghe Medical, in collaboration with Alibaba Cloud, marks a significant advancement in AI applications in the medical imaging sector [1][12] - The MIIA-X1 represents a shift from the 1.0 era of "single-scenario tool" to a 2.0 phase characterized by a "data-model-computing power" integration [1][5] Group 1: Market Trends - The concept of integrated machines has gained traction following the emergence of large models, with enterprises preferring local deployment for security and cost-effectiveness [2][3] - The demand for integrated machines has surged across various industries, particularly in finance, education, healthcare, and government sectors, driven by the need for data security [3][15] - Despite the initial excitement, many enterprises face challenges in effectively utilizing integrated machines, leading to underutilization [3][5] Group 2: Technological Advancements - The "影禾觅芽®" model, developed by Yinghe Medical, utilizes millions of multimodal medical imaging data for training, significantly enhancing the capabilities of AI in medical imaging [6][13] - The MIIA-X1 integrates the "影禾觅芽®" model with hardware, allowing for a comprehensive solution that adapts AI to hospital needs rather than the other way around [12][14] - The collaboration between Yipai Sunshine, Yinghe Medical, and Alibaba Cloud aims to transition medical AI from experimental technology to a standard clinical tool [14][15] Group 3: Industry Applications - AI's integration into the medical field is expected to enhance efficiency, reduce patient wait times, and improve overall healthcare experiences [15][16] - Leading hospitals are already implementing large models for various applications, such as personalized treatment plans and enhanced diagnostic capabilities [16][17] - The future development of AI in healthcare will focus on building standardized research databases, optimizing model training efficiency, and developing specialized AI tools for specific medical needs [17]

Core Viewpoint - The company has established a wholly-owned subsidiary, Orbiva Limited, in Hong Kong to expand its healthcare business, leveraging its expertise in IoT and smart control technologies [1][2] Group 1: Company Establishment - Orbiva Limited was officially registered on September 22, 2025, under Hong Kong's Companies Ordinance and other applicable laws [1] - The new subsidiary will serve as a strategic core for the company, focusing on broader healthcare-related business opportunities [1] Group 2: Business Strategy - The company aims to maintain its existing product-based healthcare operations while independently operating Orbiva Limited [1] - Orbiva Limited will focus on developing an AIoT-enabled home healthcare platform and ecosystem, integrating hardware, software, data, and services [1] Group 3: Future Development - The board is optimistic about Orbiva Limited's future, exploring collaborations with renowned academic institutions for joint laboratories [2] - The company is in discussions with leading hardware suppliers for product definition and development [2] - Initial communications are underway with fintech institutions to explore innovative business models [2]